[go: up one dir, main page]

ECSP15026557A - Compuestos y sus métodos de empleo - Google Patents

Compuestos y sus métodos de empleo

Info

Publication number
ECSP15026557A
ECSP15026557A ECIEPI201526557A ECPI201526557A ECSP15026557A EC SP15026557 A ECSP15026557 A EC SP15026557A EC IEPI201526557 A ECIEPI201526557 A EC IEPI201526557A EC PI201526557 A ECPI201526557 A EC PI201526557A EC SP15026557 A ECSP15026557 A EC SP15026557A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
inhibit glutaminase
cancer
employing
Prior art date
Application number
ECIEPI201526557A
Other languages
English (en)
Inventor
Rene M Lemieux
Jeremy Travins
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of ECSP15026557A publication Critical patent/ECSP15026557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. En la presente también se describen métodos para emplear los compuestos que inhiben la glutaminasa en el tratamiento del cáncer.
ECIEPI201526557A 2012-11-22 2015-06-22 Compuestos y sus métodos de empleo ECSP15026557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof

Publications (1)

Publication Number Publication Date
ECSP15026557A true ECSP15026557A (es) 2016-01-29

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201526557A ECSP15026557A (es) 2012-11-22 2015-06-22 Compuestos y sus métodos de empleo

Country Status (36)

Country Link
US (2) US10087172B2 (es)
EP (2) EP2922850B1 (es)
JP (2) JP6333277B2 (es)
KR (1) KR20150085079A (es)
CN (2) CN104936954B (es)
AR (1) AR093598A1 (es)
AU (2) AU2013347771B2 (es)
BR (1) BR112015011830A2 (es)
CA (1) CA2893510C (es)
CL (1) CL2015001392A1 (es)
CR (1) CR20150316A (es)
CY (1) CY1120581T1 (es)
DK (1) DK2922850T3 (es)
EA (2) EA030646B1 (es)
EC (1) ECSP15026557A (es)
ES (1) ES2690390T3 (es)
HR (1) HRP20181628T1 (es)
HU (1) HUE040111T2 (es)
IL (1) IL238958B (es)
LT (1) LT2922850T (es)
MX (1) MX367389B (es)
MY (1) MY177344A (es)
NZ (1) NZ708382A (es)
PE (1) PE20151072A1 (es)
PH (2) PH12015501150B1 (es)
PL (1) PL2922850T3 (es)
PT (1) PT2922850T (es)
RS (1) RS57859B1 (es)
SA (1) SA515360469B1 (es)
SG (2) SG11201504049VA (es)
SI (1) SI2922850T1 (es)
SM (1) SMT201800504T1 (es)
TR (1) TR201812360T4 (es)
TW (2) TW201906825A (es)
UA (1) UA117360C2 (es)
WO (3) WO2014079011A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2014078645A1 (en) 2012-11-16 2014-05-22 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
WO2014081925A1 (en) 2012-11-21 2014-05-30 Agios Pharmaceuticals, Inc. Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
AU2013356241A1 (en) * 2012-12-03 2015-07-09 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
JP6554037B2 (ja) 2013-01-15 2019-07-31 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
EA201991183A1 (ru) * 2014-01-06 2020-02-28 Ризен Фармасьютикалз Са Новые ингибиторы глутаминазы
MX2016012244A (es) 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compuestos y sus metodos de uso.
PE20161436A1 (es) 2014-04-30 2017-01-08 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
DK3164394T3 (da) * 2014-07-03 2020-05-04 Univ Texas Gls1-inhibitorer til behandling af sygdomme
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
US10316030B2 (en) 2014-08-07 2019-06-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) * 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
KR20170132333A (ko) 2015-04-06 2017-12-01 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제에 의한 폐암의 치료
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
CN107921044B (zh) 2015-06-30 2022-01-21 德州大学系统董事会 用于治疗疾病的gls1抑制剂
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN106890184B (zh) * 2015-12-18 2019-06-25 诺言医药科技(上海)有限公司 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用
US10150753B2 (en) 2015-12-22 2018-12-11 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
EP3503893A4 (en) 2016-08-25 2020-04-29 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINE INHIBITORS
EA201990567A1 (ru) * 2016-08-25 2019-08-30 Калитера Байосайенсиз, Инк. Комбинированная терапия с ингибиторами глутаминазы
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
US20210403479A1 (en) 2018-11-08 2021-12-30 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
JPH08508270A (ja) 1993-03-29 1996-09-03 ビーエーエスエフ アクチエンゲゼルシャフト マルチ・ドラッグ耐性のモジュレーターとしての１−アミノ−３−フェノキシ−プロパン誘導体
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
ES2237919T4 (es) 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
KR20100087330A (ko) 2007-11-19 2010-08-04 제넨테크, 인크. 종양 진행을 억제하기 위한 조성물 및 방법
EP2271941B1 (en) 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
EP2419177A1 (en) 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
EP3206034B1 (en) 2010-06-23 2020-05-27 University of Louisville Research Foundation, Inc. Use of fatty acids in methods for detecting cancer
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2782570B1 (en) * 2011-11-21 2019-09-18 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
KR20140138956A (ko) 2012-03-15 2014-12-04 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 Ｅ-카드헤린의 세포외 도메인의 저해제를 포함하는 병용 치료법
WO2014081925A1 (en) 2012-11-21 2014-05-30 Agios Pharmaceuticals, Inc. Glutamase inhibitors and method of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
EA201991183A1 (ru) 2014-01-06 2020-02-28 Ризен Фармасьютикалз Са Новые ингибиторы глутаминазы
MX2016012244A (es) 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compuestos y sus metodos de uso.

Also Published As

Publication number Publication date
AU2013347771B2 (en) 2018-02-01
LT2922850T (lt) 2018-09-10
UA117360C2 (uk) 2018-07-25
EP2922850A1 (en) 2015-09-30
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
EP3456719A1 (en) 2019-03-20
EP2922850A4 (en) 2016-05-18
JP2016500082A (ja) 2016-01-07
EA030646B1 (ru) 2018-09-28
TW201427963A (zh) 2014-07-16
WO2014079011A1 (en) 2014-05-30
SG11201504049VA (en) 2015-07-30
IL238958A0 (en) 2015-07-30
PL2922850T3 (pl) 2018-12-31
HUE040111T2 (hu) 2019-02-28
NZ708382A (en) 2020-04-24
AU2013347771A1 (en) 2015-06-11
MY177344A (en) 2020-09-13
ES2690390T3 (es) 2018-11-20
BR112015011830A2 (pt) 2017-07-11
WO2014079150A1 (en) 2014-05-30
AU2018202954A1 (en) 2018-05-17
EA201890754A1 (ru) 2018-08-31
PH12017502141A1 (en) 2019-02-27
CR20150316A (es) 2015-08-28
RS57859B1 (sr) 2018-12-31
DK2922850T3 (en) 2018-10-08
TR201812360T4 (tr) 2018-09-21
HRP20181628T1 (hr) 2018-12-14
SMT201800504T1 (it) 2018-11-09
US20190084976A1 (en) 2019-03-21
IL238958B (en) 2019-09-26
US10087172B2 (en) 2018-10-02
AR093598A1 (es) 2015-06-10
PH12015501150A1 (en) 2015-08-17
JP2018150316A (ja) 2018-09-27
CN108727307A (zh) 2018-11-02
PT2922850T (pt) 2018-10-15
SA515360469B1 (ar) 2017-07-11
EP2922850B1 (en) 2018-07-18
US10689375B2 (en) 2020-06-23
CN104936954A (zh) 2015-09-23
MX367389B (es) 2019-08-19
SG10201609940RA (en) 2016-12-29
HK1214593A1 (en) 2016-07-29
SI2922850T1 (sl) 2018-10-30
CY1120581T1 (el) 2019-07-10
US20150291576A1 (en) 2015-10-15
TW201906825A (zh) 2019-02-16
WO2014079136A1 (en) 2014-05-30
CN104936954B (zh) 2018-08-14
PE20151072A1 (es) 2015-08-26
CA2893510C (en) 2021-01-19
CA2893510A1 (en) 2014-05-30
EA201590987A1 (ru) 2015-12-30
PH12015501150B1 (en) 2018-05-04
TWI629268B (zh) 2018-07-11
JP6333277B2 (ja) 2018-05-30
CL2015001392A1 (es) 2016-04-22

Similar Documents

Publication Publication Date Title
ECSP15026557A (es) Compuestos y sus métodos de empleo
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
UY34538A (es) Heteroarilos y usos de los mismos
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2015003140A (es) Formulaciones de enzalutamida.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX2015010312A (es) Metodos para tratamiento del melanoma.
CL2016003260A1 (es) Profármacos de gemcitabina
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
MX2018010993A (es) Derivados de icariina e icaritina.